In this episode we discuss how technology, health data and a multidisciplinary team with expertise and passion in data science and health industries, can make a powerful difference to how patients access treatment. By creating real world insights and visualising where and when there is opportunity to improve the treatment experience, we are supporting pharma companies in their quest to make a positive impact on treatment outcomes and patient experience
The last 2 years has seen a global boom in emerging technology within the health industry. The demand for software & product engineers, data scientists, UI/UX designer and health & market expertise has increased accordingly. For a fast growing company, with ambition to offer our data analytics technology to other countries, ingesting new and higher volumes of health data, as well as expanding our product capabilities to new customers. What does this mean for our talent acquisition strategy. How do we find the right expertise in these highly skilled professions? Our vision is inspiring, our company is growing fast and our team and culture is important to our success. What qualities do we look for and what does a Prospection career offer? Stef Freeman, Prospection Head of Talent Acquisition shares her views.
Prospection is a trusted 3rd party provider, operating as an intermediary between data custodians and end users of the data. We help find elements in data to benefit the public good, offering insights to understand patients and improve disease associated outcomes. In this podcast Head of Data & Partnerships, Dr Peter Cronin introduces the different types of data, compares the benefits of real world evidence and clinical trial data. Answering questions on how we turn data into real world evidence? Why we need real world data? How we overcome the challenges of quality data access? How Prospection adds value through data?
In this forum, we get to dive into the concept of finding patients using a combination of data and technology to get patients diagnosed earlier and onto the right treatments. How can this be achieved? What is the value both to the industry and to the patient? What are our current capabilities? and where is all this heading moving forward? The podcast is joined by the head of Australian and New Zealand at Prospection Greg Hughes.